RJA
CYTK icon

Ross\Johnson & Associates’s Cytokinetics CYTK Stock Holding History

Ross\Johnson & Associates’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2
Closed -$127 – 249
2025
Q4 		$127 Buy
+2
New +$124 ﹤0.01% 283

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ross\Johnson & Associates's CYTK Position: Q1 2026 in Review

Ross\Johnson & Associates sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 2 shares — an estimated $127 sold.

Ross\Johnson & Associates first reported a position in CYTK in Q4 2025 and held it in 1 quarter. The position peaked at $127 in Q4 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Ross\Johnson & Associates reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
  • Ross\Johnson & Associates sold 2 Cytokinetics shares in Q1 2026, an estimated $127.
  • Ross\Johnson & Associates first reported a position in Cytokinetics in Q4 2025 and held it in 1 quarter.
  • Ross\Johnson & Associates's Cytokinetics position peaked at $127 in Q4 2025.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Ross\Johnson & Associates's 13F filing for Q1 2026, filed 8 May 2026.